Alto Neuroscience, Inc. (ANRO)
NYSE · Healthcare · Biotechnology
$24.01−3.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $942M
- 52-week range
- $5.23 – $37.48
- 52-week change
- +317.51%
- EPS (trailing)
- −$2.31
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$63.2M
- Diluted EPS
- −$2.19
- Free cash flow
- −$51.8M
From the company’s annual report on SEC EDGAR.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease.
Headquarters: Mountain View, United States · 68 employees · altoneuroscience.com